Bleeding Risk Management in Patients on Dual Antithrombotic Therapy with Garlic Supplement Use

Garlic Supplement Risks

Garlic supplements contain compounds that inhibit thromboxane synthetase and reduce platelet aggregation, creating a theoretical increase in bleeding risk when combined with antiplatelet (clopidogrel) and anticoagulant (apixaban) therapy. Evidence level: low (in‑vitro/experimental) 1
Concentrated garlic supplements pose a greater theoretical bleeding risk than dietary garlic, supporting the recommendation to discontinue garlic supplements in patients receiving dual antithrombotic therapy. Evidence level: low (theoretical) 1

Pantoprazole, dexlansoprazole, or lansoprazole are recommended for patients with multiple bleeding risk factors—including those on clopidogrel + apixaban—to reduce gastrointestinal bleeding. Evidence level: moderate (guideline‑based recommendation) 2, 3
A history of gastrointestinal bleeding or peptic ulcer disease identifies patients at higher risk for major bleeding on dual antithrombotic therapy; these patients should receive PPI prophylaxis. Evidence level: moderate (observational data supporting guideline) 2, 3

Omeprazole has the strongest evidence for a pharmacokinetic interaction that reduces clopidogrel’s antiplatelet effect, making it a less suitable PPI choice in this context. Evidence level: moderate (clinical pharmacology studies) 2, 3
Consequently, pantoprazole, dexlansoprazole, or lansoprazole are preferred alternatives when a PPI is needed for patients on clopidogrel. Evidence level: moderate (clinical guideline recommendation) 2, 3

The American College of Cardiology indicates that dual antithrombotic therapy (antiplatelet plus anticoagulant) increases major bleeding events 3.4-fold compared to monotherapy, with bleeding requiring transfusion or surgical intervention being the primary concern 4
The combination of anticoagulant and antiplatelet therapy increases major extracranial bleeding with an odds ratio of 2.4 (95% CI: 1.4 to 4.1), meaning as few as 67 patients need treatment to cause 1 additional major bleeding event 5, 6, 7

The American College of Cardiology recommends discontinuing Ashwagandha immediately if the patient is currently taking it with clopidogrel and apixaban 4
Verify that dual therapy (clopidogrel + apixaban) is still clinically indicated, as this combination should only be used in specific high-risk scenarios such as atrial fibrillation patients with recent coronary stenting 4
Prescribe a proton pump inhibitor (PPI) such as pantoprazole, dexlansoprazole, or lansoprazole to reduce gastrointestinal bleeding risk 4, 7, 8

Monitor closely if the patient has any of these high-risk features, including age over 75 years, history of gastrointestinal bleeding, peptic ulcer disease, renal impairment, or body weight <60 kg 4, 5, 9

Apixaban monotherapy may be sufficient for stroke prevention in atrial fibrillation without adding clopidogrel 9
Clopidogrel monotherapy may be appropriate for coronary artery disease without atrial fibrillation 5, 6